Lung disease in systemic sclerosis
Interstitial lung disease in systemic sclerosis.
Papers per year
Each bar is 12 months; the last one ends 17 Oct 2026. New trials in the same years: 11, 10, 20, 18, 21.
New guidelines and consensus this year
- Guide from the Colegio Mexicano de Reumatología for the Pharmacological Treatment of Systemic Sclerosis Part 1: Cutaneous Involvement, Interstitial Lung Disease, and Pulmonary Arterial HypertensionReumatol Clin (Engl Ed)2026 May
- ERS/EULAR clinical practice guidelines for connective tissue disease-associated interstitial lung diseaseEur Respir J2026 Jan
- ERS/EULAR clinical practice guidelines for connective tissue disease-associated interstitial lung disease developed by the task force for connective tissue disease-associated interstitial lung disease of the European Respiratory Society (ERS) and the European Alliance of Associations for Rheumatology (EULAR) Endorsed by the European Reference Network on rare respiratory diseases (ERN-LUNG)Ann Rheum Dis2026 Jan
- Early detection of interstitial lung disease in rheumatic diseases: A joint statement from the Portuguese Pulmonology Society, the Portuguese Rheumatology Society, and the Portuguese Radiology and Nuclear Medicine SocietyPulmonology2025 Dec 31
All papers from the last 12 months
379 papers (18 Oct 2025 – 17 Oct 2026), newest first. Loading the full list…
- Connective tissue disease-associated interstitial lung disease: immune profiling and correlation of immune cells with pulmonary function in SSc-ILDAnn Med2026 DecPMID 42876296
- The clinical profile of systemic sclerosis without a 'scleroderma pattern' at nailfold capillaroscopy: results from the multicenter SPRING registry of the Italian Society of RheumatologyJ Transl Autoimmun2026 DecPMID 42367240
- Artificial intelligence for lung disease quantification in systemic sclerosis-associated interstitial lung disease and other connective tissue disease-associated interstitial lung diseaseCurr Opin Rheumatol2026 Nov 1PMID 42712118Review
- Redefining systemic sclerosis-associated pulmonary hypertension as an immune-mediated vasculopathy across the cardiopulmonary circulationCurr Opin Rheumatol2026 Nov 1PMID 42687395Review
- Advanced imaging in systemic sclerosis: distinguishing activity from damage across organ systemsCurr Opin Rheumatol2026 Nov 1PMID 42559703Review
- Hyper-aging in systemic sclerosis: linking genome instability, mitochondrial dysfunction, and inflammaging to fibrosisCurr Opin Rheumatol2026 Nov 1PMID 42559700Review
- Sarcopenia in systemic sclerosis-associated interstitial lung disease: A cross-sectional radiological and functional assessmentMedicine (Baltimore)2026 Oct 16PMID 42888533
- Outcomes of systemic sclerosis with overlapping myositis: a propensity score-matched cohort studyRheumatology (Oxford)2026 Oct 16PMID 42886520
- Interstitial lung disease as the initial manifestation of systemic autoimmune disease: a narrative review of autoantibodies, biomarkers, prognosis, and managementClin Exp Rheumatol2026 Oct 13PMID 42873695Review
- Impact of timing of interstitial lung disease in patients with systemic sclerosisThorax2026 Oct 13PMID 42869658
More rheumatology trends
All specialties →New lupus treatments
Anifrolumab, belimumab and other targeted drugs in systemic lupus.
Key point: Biologics have been increasingly incorporated into the treatment algorithm at earlier stages of SLE and are first-line treatments for certain manifestations such as lupus nephritis.
Rheumatic immune-related adverse events
Arthritis, myositis and other rheumatic side effects of checkpoint inhibitors.
Ultrasound in rheumatology
Musculoskeletal and vascular ultrasound for diagnosis and monitoring.
Giant cell arteritis and PMR
Giant cell arteritis, polymyalgia rheumatica and steroid-sparing treatment.
Key point: In PMR, interleukin-6 receptor blockers should be considered with glucocorticoids for relapsing disease and can be considered for new-onset high-risk patients.
Psoriatic arthritis
Psoriatic arthritis and its targeted treatments.
JAK inhibitors in rheumatoid arthritis
JAK inhibitors in RA, including their safety.
Too many papers to read?
PubDaily picks the ones that matter in your specialty and summarises them, about 10 minutes a week.
How these numbers are counted
PubMed query, searched in titles and abstracts by publication date:
"systemic sclerosis"[tiab] AND ("interstitial lung disease"[tiab] OR ILD[tiab])Trials: ClinicalTrials.gov studies first submitted in each 12-month window that match the same terms. A query can miss synonyms or catch unrelated papers, so treat counts as approximate.